TerminatedNot Applicable

Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma Patients

Stopped: Insufficient accrual

United States6 participantsStarted 2018-09-05

Plain-language summary

This pilot trial studies how well serial liquid biopsies work in detecting microsatellite instability in participants with stage IV colorectal cancer. Serial liquid biopsies may help doctors learn better methods to track cancer in the bloodstream and how to use these to improve cancer treatments.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients newly diagnosed with stage IV colorectal cancer and with defined microsatellite instability status before initiation of systemic immunotherapy. * Trackable cancer-driver mutation in the primary tumor documented before initiation of chemotherapy. * Zubrod performance status of 0 or 1. * Patients have measurable disease according to RECIST version (v)1.1. * Ability to understand and willing to sign a written informed consent. Exclusion Criteria: * Severe anemia (hemoglobin \[Hb\] \< 8 g/dL).

What they're measuring

Correlation between presence of MSI present in circulating tumor DNA versus in primary tumor specimens

Timeframe: Up to 1 year

Trial details

NCT IDNCT03594448

SponsorUniversity of Southern California

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-09-18

View on ClinicalTrials.gov More Microsatellite Instability trials